
Lumos Diagnostics continues to expand its commercial footprint through FDA clearance, growing U.S. adoption, manufacturing partnerships, and paediatric research. The company now focuses on turning regulatory success and market access into recurring sales, broader reimbursement, and sustainable long-term growth.
.webp&w=828&q=75)
Lumos Diagnostics shares have dropped sharply after last year’s rally, with weak technical signals and dilution concerns weighing on sentiment. Despite long-term optimism around FebriDx and US commercialisation, investors remain cautious due to slow revenue growth and ongoing funding pressures.